person · Reporting owner
Pacelli Steven Robert
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| DEXCOM INCDXCM · Entity 3114 | EVP Managing Director Dexcom V | November 24, 2023 | November 27, 2023 |
| ProSomnus, Inc.OSA · Entity 94197 | Director | December 06, 2022 | February 16, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
DEXCOM INC
Report date November 24, 2023 · Filed November 27, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 124,775 |
Reported balance
After 2023-11-24 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-11-24 · Sale · Disposed 411 · Balance 124,775 F1: On September 15, 2022, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan that was intended to comply with prior version of Rule 10b5-1 promulgated under the Securities Exchange Act of 1934, as amended. F2: Included in this number are 39,132 unvested restricted stock units, 18,776 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 13,288 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 7,068 of which were granted on March 8, 2021 and shall vest through March 8, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: On September 15, 2022, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan that was intended to comply with prior version of Rule 10b5-1 promulgated under the Securities Exchange Act of 1934, as amended.
F2: Included in this number are 39,132 unvested restricted stock units, 18,776 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 13,288 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 7,068 of which were granted on March 8, 2021 and shall vest through March 8, 2024.
ProSomnus, Inc.
Report date December 06, 2022 · Filed February 16, 2024 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 18,200 |
Reported balance
Holding disclosure · report date 2022-12-06 · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · Balance 18,200 F1: Holdings have been adjusted to rectify unintentional underreporting in the Reporting Person's Form 3. |
Filing footnotes · ownership attribution and instrument terms
F1: Holdings have been adjusted to rectify unintentional underreporting in the Reporting Person's Form 3.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 12, 2019 Filed Mar 13, 2019 23:01 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 2,222 | $142.79 | $317,284.27 |
DisclosureSEC source: 0001093557-19-000084 · edgardoc.xml · nonDerivative · entry 3 Pacelli Steven Robert · CIK 0001359098 · EVP Strategy and Corporate Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,913 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 49,825 unvested restricted stock units, 14,987 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 25,668 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 9,170 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| March 12, 2019 Filed Mar 13, 2019 23:01 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 6,399 | $142.79 | $913,727.29 |
DisclosureSEC source: 0001093557-19-000084 · edgardoc.xml · nonDerivative · entry 2 Pacelli Steven Robert · CIK 0001359098 · EVP Strategy and Corporate Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,135 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 49,825 unvested restricted stock units, 14,987 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 25,668 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 9,170 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| March 12, 2019 Filed Mar 13, 2019 23:01 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 2,190 | $142.79 | $312,714.92 |
DisclosureSEC source: 0001093557-19-000084 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · EVP Strategy and Corporate Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,534 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 49,825 unvested restricted stock units, 14,987 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 25,668 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 9,170 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| March 08, 2019 Filed Mar 12, 2019 00:38 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 14,987 | $0.00 | $14.99 |
DisclosureSEC source: 0001093557-19-000055 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · EVP Strategy and Corporate Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,724 F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting over a 36 month period from the date of grant as follows: 1/3 shall vest 12 months from the Grant Date, and the remaining balance shall vest in four equal installments over the following 24 months. Share units represent a contingent right to receive one share of DexCom, Inc. common stock. F2 · balance_after: Included in this number are 49,825 unvested restricted stock units, 14,987 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 25,668 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 9,170 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| February 22, 2019 Filed Feb 27, 2019 00:58 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 333 | $153.80 | $51,216.30 |
DisclosureSEC source: 0001093557-19-000044 · wf-form4_155122907767740.xml · nonDerivative · entry 6 Pacelli Steven Robert · CIK 0001359098 · EVP Strategy and Corporate Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,737 F1 · shares: On June 11, 2018, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $153.69 to $153.89. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issurer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 58,591 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 13,755 of which were granted on March 8, 2017 and shall vest through March 8, 2020, and 6,334 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| February 22, 2019 Filed Feb 27, 2019 00:58 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 147 | $151.78 | $22,311.66 |
DisclosureSEC source: 0001093557-19-000044 · wf-form4_155122907767740.xml · nonDerivative · entry 5 Pacelli Steven Robert · CIK 0001359098 · EVP Strategy and Corporate Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,070 F1 · shares: On June 11, 2018, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F3 · balance_after: Included in this number are 58,591 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 13,755 of which were granted on March 8, 2017 and shall vest through March 8, 2020, and 6,334 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| February 22, 2019 Filed Feb 27, 2019 00:58 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 154 | $144.06 | $22,185.96 |
DisclosureSEC source: 0001093557-19-000044 · wf-form4_155122907767740.xml · nonDerivative · entry 4 Pacelli Steven Robert · CIK 0001359098 · EVP Strategy and Corporate Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,217 F1 · shares: On June 11, 2018, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $144.04 to $144.08. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 58,591 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 13,755 of which were granted on March 8, 2017 and shall vest through March 8, 2020, and 6,334 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| February 22, 2019 Filed Feb 27, 2019 00:58 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 93 | $142.64 | $13,265.52 |
DisclosureSEC source: 0001093557-19-000044 · wf-form4_155122907767740.xml · nonDerivative · entry 3 Pacelli Steven Robert · CIK 0001359098 · EVP Strategy and Corporate Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,371 F1 · shares: On June 11, 2018, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F3 · balance_after: Included in this number are 58,591 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 13,755 of which were granted on March 8, 2017 and shall vest through March 8, 2020, and 6,334 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| February 22, 2019 Filed Feb 27, 2019 00:58 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 115 | $141.47 | $16,268.48 |
DisclosureSEC source: 0001093557-19-000044 · wf-form4_155122907767740.xml · nonDerivative · entry 2 Pacelli Steven Robert · CIK 0001359098 · EVP Strategy and Corporate Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,464 F1 · shares: On June 11, 2018, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F3 · balance_after: Included in this number are 58,591 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 13,755 of which were granted on March 8, 2017 and shall vest through March 8, 2020, and 6,334 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| February 22, 2019 Filed Feb 27, 2019 00:58 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 825 | $140.50 | $115,909.45 |
DisclosureSEC source: 0001093557-19-000044 · wf-form4_155122907767740.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · EVP Strategy and Corporate Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,579 F1 · shares: On June 11, 2018, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $140.11 to $140.84. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 58,591 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 13,755 of which were granted on March 8, 2017 and shall vest through March 8, 2020, and 6,334 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| January 23, 2019 Filed Jan 24, 2019 22:46 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 3,114 | $149.74 | $466,302.50 |
DisclosureSEC source: 0001093557-19-000014 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · EVP, Strategy & Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,404 F1 · shares: On June 11, 2018, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $149.50 to $150.00. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 58,591 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 13,755 of which were granted on March 8, 2017 and shall vest through March 8, 2020, and 6,334 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| December 21, 2018 Filed Dec 27, 2018 01:22 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 377 | $110.97 | $41,835.69 |
DisclosureSEC source: 0001093557-18-000257 · edgardoc.xml · nonDerivative · entry 3 Pacelli Steven Robert · CIK 0001359098 · EVP, Strategy & Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,518 F1 · shares: On June 11, 2018, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F3 · balance_after: Included in this number are 58,591 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 13,755 of which were granted on March 8, 2017 and shall vest through March 8, 2020, and 6,334 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| December 21, 2018 Filed Dec 27, 2018 01:22 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,960 | $109.57 | $214,759.16 |
DisclosureSEC source: 0001093557-18-000257 · edgardoc.xml · nonDerivative · entry 2 Pacelli Steven Robert · CIK 0001359098 · EVP, Strategy & Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,895 F1 · shares: On June 11, 2018, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $109.09 to $109.87. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 58,591 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 13,755 of which were granted on March 8, 2017 and shall vest through March 8, 2020, and 6,334 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| December 21, 2018 Filed Dec 27, 2018 01:22 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 777 | $108.24 | $84,105.35 |
DisclosureSEC source: 0001093557-18-000257 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · EVP, Strategy & Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,855 F1 · shares: On June 11, 2018, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $107.97 to $108.74. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 58,591 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 13,755 of which were granted on March 8, 2017 and shall vest through March 8, 2020, and 6,334 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| November 23, 2018 Filed Nov 27, 2018 23:27 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 700 | $122.04 | $85,425.97 |
DisclosureSEC source: 0001093557-18-000243 · edgardoc.xml · nonDerivative · entry 3 Pacelli Steven Robert · CIK 0001359098 · EVP, Strategy & Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,632 F1 · shares: On June 11, 2018, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $122.03 to $122.05. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issurer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 58,591 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 13,755 of which were granted on March 8, 2017 and shall vest through March 8, 2020, and 6,334 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| November 23, 2018 Filed Nov 27, 2018 23:27 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,814 | $121.71 | $220,788.65 |
DisclosureSEC source: 0001093557-18-000243 · edgardoc.xml · nonDerivative · entry 2 Pacelli Steven Robert · CIK 0001359098 · EVP, Strategy & Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,332 F1 · shares: On June 11, 2018, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $121.03 to $122.00. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 58,591 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 13,755 of which were granted on March 8, 2017 and shall vest through March 8, 2020, and 6,334 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| November 23, 2018 Filed Nov 27, 2018 23:27 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 600 | $119.82 | $71,890.02 |
DisclosureSEC source: 0001093557-18-000243 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · EVP, Strategy & Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,146 F1 · shares: On June 11, 2018, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $119.64 to $120.21. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 58,591 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 13,755 of which were granted on March 8, 2017 and shall vest through March 8, 2020, and 6,334 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| October 23, 2018 Filed Oct 26, 2018 00:58 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,100 | $129.30 | $142,232.53 |
DisclosureSEC source: 0001093557-18-000222 · edgardoc.xml · nonDerivative · entry 2 Pacelli Steven Robert · CIK 0001359098 · EVP, Strategy & Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,746 F1 · shares: On June 11, 2018, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $129.06 to $129.78. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 58,591 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 13,755 of which were granted on March 8, 2017 and shall vest through March 8, 2020, and 6,334 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| October 23, 2018 Filed Oct 26, 2018 00:58 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 2,014 | $128.61 | $259,020.94 |
DisclosureSEC source: 0001093557-18-000222 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · EVP, Strategy & Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,846 F1 · shares: On June 11, 2018, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $128.06 to $129.02. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 58,591 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 13,755 of which were granted on March 8, 2017 and shall vest through March 8, 2020, and 6,334 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| September 24, 2018 Filed Sep 27, 2018 00:32 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 40 | $142.77 | $5,710.60 |
DisclosureSEC source: 0001093557-18-000208 · edgardoc.xml · nonDerivative · entry 5 Pacelli Steven Robert · CIK 0001359098 · EVP, Strategy & Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,860 F1 · shares: On June 11, 2018, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F7 · price: This transaction was executed in multiple trades at prices ranging from $142.74 to $142.79. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 58,591 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 13,755 of which were granted on March 8, 2017 and shall vest through March 8, 2020, and 6,334 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| September 24, 2018 Filed Sep 27, 2018 00:32 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 984 | $142.17 | $139,896.56 |
DisclosureSEC source: 0001093557-18-000208 · edgardoc.xml · nonDerivative · entry 4 Pacelli Steven Robert · CIK 0001359098 · EVP, Strategy & Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,900 F1 · shares: On June 11, 2018, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F6 · price: This transaction was executed in multiple trades at prices ranging from $141.74 to $142.67. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 58,591 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 13,755 of which were granted on March 8, 2017 and shall vest through March 8, 2020, and 6,334 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| September 24, 2018 Filed Sep 27, 2018 00:32 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,640 | $141.07 | $231,358.41 |
DisclosureSEC source: 0001093557-18-000208 · edgardoc.xml · nonDerivative · entry 3 Pacelli Steven Robert · CIK 0001359098 · EVP, Strategy & Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,884 F1 · shares: On June 11, 2018, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $140.71 to $141.66. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issurer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 58,591 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 13,755 of which were granted on March 8, 2017 and shall vest through March 8, 2020, and 6,334 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| September 24, 2018 Filed Sep 27, 2018 00:32 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 300 | $140.24 | $42,072.00 |
DisclosureSEC source: 0001093557-18-000208 · edgardoc.xml · nonDerivative · entry 2 Pacelli Steven Robert · CIK 0001359098 · EVP, Strategy & Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,524 F1 · shares: On June 11, 2018, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $139.70 to $140.55. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 58,591 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 13,755 of which were granted on March 8, 2017 and shall vest through March 8, 2020, and 6,334 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| September 24, 2018 Filed Sep 27, 2018 00:32 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 150 | $138.69 | $20,803.50 |
DisclosureSEC source: 0001093557-18-000208 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · EVP, Strategy & Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,824 F1 · shares: On June 11, 2018, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $138.53 to $139.02. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 58,591 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 13,755 of which were granted on March 8, 2017 and shall vest through March 8, 2020, and 6,334 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| September 10, 2018 Filed Sep 13, 2018 01:21 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 2,303 | $143.76 | $331,068.23 |
DisclosureSEC source: 0001093557-18-000198 · edgardoc.xml · nonDerivative · entry 2 Pacelli Steven Robert · CIK 0001359098 · EVP, Strategy & Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,974 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 58,591 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 13,755 of which were granted on March 8, 2017 and shall vest through March 8, 2020, and 6,334 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| September 10, 2018 Filed Sep 13, 2018 01:21 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 3,180 | $143.76 | $457,141.54 |
DisclosureSEC source: 0001093557-18-000198 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · EVP, Strategy & Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,277 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 58,591 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 13,755 of which were granted on March 8, 2017 and shall vest through March 8, 2020, and 6,334 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| August 23, 2018 Filed Aug 27, 2018 21:20 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 100 | $143.09 | $14,309.00 |
DisclosureSEC source: 0001093557-18-000173 · edgardoc.xml · nonDerivative · entry 4 Pacelli Steven Robert · CIK 0001359098 · EVP, Strategy & Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,457 F1 · shares: On June 11, 2018, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F3 · balance_after: Included in this number are 69,509 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 18,340 of which were granted on March 8, 2017 and shall vest through March 8, 2020, and 12,667 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| August 23, 2018 Filed Aug 27, 2018 21:20 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 50 | $141.30 | $7,065.00 |
DisclosureSEC source: 0001093557-18-000173 · edgardoc.xml · nonDerivative · entry 3 Pacelli Steven Robert · CIK 0001359098 · EVP, Strategy & Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,557 F1 · shares: On June 11, 2018, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F3 · balance_after: Included in this number are 69,509 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 18,340 of which were granted on March 8, 2017 and shall vest through March 8, 2020, and 12,667 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| August 23, 2018 Filed Aug 27, 2018 21:20 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 750 | $140.34 | $105,256.50 |
DisclosureSEC source: 0001093557-18-000173 · edgardoc.xml · nonDerivative · entry 2 Pacelli Steven Robert · CIK 0001359098 · EVP, Strategy & Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,607 F1 · shares: On June 11, 2018, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $140.15 to $141.08. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 69,509 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 18,340 of which were granted on March 8, 2017 and shall vest through March 8, 2020, and 12,667 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| August 23, 2018 Filed Aug 27, 2018 21:20 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 2,214 | $139.66 | $309,213.00 |
DisclosureSEC source: 0001093557-18-000173 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · EVP, Strategy & Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,357 F1 · shares: On June 11, 2018, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $139.11 to $140.03. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 69,509 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 18,340 of which were granted on March 8, 2017 and shall vest through March 8, 2020, and 12,667 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| July 25, 2018 Filed Jul 27, 2018 21:09 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,458 | $102.41 | $149,312.76 |
DisclosureSEC source: 0001093557-18-000153 · edgardoc.xml · nonDerivative · entry 2 Pacelli Steven Robert · CIK 0001359098 · EVP, Strategy & Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,571 F1 · shares: On June 11, 2018, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $102.09 to $102.60. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 69,509 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 18,340 of which were granted on March 8, 2017 and shall vest through March 8, 2020, and 12,667 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| July 25, 2018 Filed Jul 27, 2018 21:09 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,656 | $101.46 | $168,022.07 |
DisclosureSEC source: 0001093557-18-000153 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · EVP, Strategy & Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,029 F1 · shares: On June 11, 2018, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $101.03 to $101.93. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 69,509 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 18,340 of which were granted on March 8, 2017 and shall vest through March 8, 2020, and 12,667 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| May 10, 2018 Filed May 12, 2018 00:03 UTC | DEXCOM INC DXCM · Entity 3114 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 2,855 | $0.00 Strike: $7.63 | $0.00 |
DisclosureSEC source: 0001093557-18-000092 · edgardoc.xml · derivative · entry 2 Pacelli Steven Robert · CIK 0001359098 · EVP, Strategy & Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,855 shares Expires 2018-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 10, 2018 Filed May 12, 2018 00:03 UTC | DEXCOM INC DXCM · Entity 3114 | Exercise / conversionCommon Stock | 2,855 | $7.63 | $21,783.65 |
DisclosureSEC source: 0001093557-18-000092 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · EVP, Strategy & Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,685 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Included in this number are 69,509 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 18,340 of which were granted on March 8, 2017 and shall vest through March 8, 2020, and 12,667 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| March 12, 2018 Filed Mar 15, 2018 01:03 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 2,221 | $60.73 | $134,882.66 |
DisclosureSEC source: 0001093557-18-000057 · edgardoc.xml · nonDerivative · entry 3 Pacelli Steven Robert · CIK 0001359098 · EVP, Strategy & Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,830 F1 · shares: These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted. F2 · balance_after: Included in this number are 69,509 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 18,340 of which were granted on March 8, 2017 and shall vest through March 8, 2020, and 12,667 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| March 12, 2018 Filed Mar 15, 2018 01:03 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 2,689 | $60.73 | $163,304.58 |
DisclosureSEC source: 0001093557-18-000057 · edgardoc.xml · nonDerivative · entry 2 Pacelli Steven Robert · CIK 0001359098 · EVP, Strategy & Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,051 F1 · shares: These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted. F2 · balance_after: Included in this number are 69,509 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 18,340 of which were granted on March 8, 2017 and shall vest through March 8, 2020, and 12,667 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| March 12, 2018 Filed Mar 15, 2018 01:03 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 4,188 | $60.73 | $254,339.75 |
DisclosureSEC source: 0001093557-18-000057 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · EVP, Strategy & Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,740 F1 · shares: These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted. F2 · balance_after: Included in this number are 69,509 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 18,340 of which were granted on March 8, 2017 and shall vest through March 8, 2020, and 12,667 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| March 08, 2018 Filed Mar 13, 2018 01:33 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 38,502 | $0.00 | $38.50 |
DisclosureSEC source: 0001093557-18-000038 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · EVP, Strategy & Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,928 F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting over a 36 month period from the date of grant as follows: 1/3 shall vest 12 months from the Grant Date, and the remaining balance shall vest in four equal installments over the following 24 months. Share units represent a contingent right to receive one share of DexCom, Inc. common stock. F2 · balance_after: Included in this number are 69,509 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 18,340 of which were granted on March 8, 2017 and shall vest through March 8, 2020, and 12,667 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| November 29, 2017 Filed Dec 1, 2017 01:57 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 2,900 | $60.12 | $174,340.46 |
DisclosureSEC source: 0001093557-17-000237 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · EVP, Strategy & Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,426 F1 · shares: On December 06, 2016 Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $60.00 to $60.46. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 54,010 unvested restricted stock units, 27,510 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 19,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019 and 7,500 of which were granted on March 8, 2015 and shall vest through March 8, 2018. Read SEC document |
| September 25, 2017 Filed Sep 27, 2017 23:49 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,450 | $69.81 | $101,218.99 |
DisclosureSEC source: 0001093557-17-000204 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · EVP, Strategy & Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,326 F1 · shares: On December 06, 2016 Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $69.59 to $70.08. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 54,010 unvested restricted stock units, 27,510 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 19,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019 and 7,500 of which were granted on March 8, 2015 and shall vest through March 8, 2018. Read SEC document |
| September 11, 2017 Filed Sep 13, 2017 22:38 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 3,964 | $71.81 | $284,668.32 |
DisclosureSEC source: 0001093557-17-000198 · edgardoc.xml · nonDerivative · entry 2 Pacelli Steven Robert · CIK 0001359098 · EVP, Strategy & Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,776 F1 · shares: These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted. F2 · balance_after: Included in this number are 54,010 unvested restricted stock units, 27,510 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 19,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019 and 7,500 of which were granted on March 8, 2015 and shall vest through March 8, 2018. Read SEC document |
| September 11, 2017 Filed Sep 13, 2017 22:38 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 3,347 | $71.81 | $240,359.45 |
DisclosureSEC source: 0001093557-17-000198 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · EVP, Strategy & Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,740 F1 · shares: These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted. F2 · balance_after: Included in this number are 54,010 unvested restricted stock units, 27,510 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 19,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019 and 7,500 of which were granted on March 8, 2015 and shall vest through March 8, 2018. Read SEC document |
| August 23, 2017 Filed Aug 24, 2017 23:31 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 3,987 | $75.26 | $300,044.87 |
DisclosureSEC source: 0001093557-17-000181 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · EVP, Strategy & Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,087 F1 · shares: On December 06, 2016 Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $74.98 to $75.62. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 67,843 unvested restricted stock units, 27,510 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 25,333 of which were granted on March 8, 2016 and shall vest through March 8, 2019 and 15,000 of which were granted on March 8, 2015 and shall vest through March 8, 2018. Read SEC document |
| July 24, 2017 Filed Jul 26, 2017 00:55 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,450 | $69.47 | $100,724.69 |
DisclosureSEC source: 0001093557-17-000163 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · EVP, Strategy & Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,074 F1 · shares: On December 06, 2016 Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $69.38 to $69.66. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 67,843 unvested restricted stock units, 27,510 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 25,333 of which were granted on March 8, 2016 and shall vest through March 8, 2019 and 15,000 of which were granted on March 8, 2015 and shall vest through March 8, 2018. Read SEC document |
| June 23, 2017 Filed Jun 27, 2017 22:55 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,450 | $78.19 | $113,377.53 |
DisclosureSEC source: 0001093557-17-000156 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · EVP, Strategy & Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,524 F1 · shares: On December 06, 2016 Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $77.77 to $78.90. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 67,843 unvested restricted stock units, 27,510 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 25,333 of which were granted on March 8, 2016 and shall vest through March 8, 2019 and 15,000 of which were granted on March 8, 2015 and shall vest through March 8, 2018. Read SEC document |
| May 23, 2017 Filed May 25, 2017 23:16 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,450 | $68.24 | $98,949.02 |
DisclosureSEC source: 0001093557-17-000129 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · EVP, Strategy & Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,974 F1 · shares: On December 06, 2016 Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $67.98 to $68.87. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 67,843 unvested restricted stock units, 27,510 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 25,333 of which were granted on March 8, 2016 and shall vest through March 8, 2019 and 15,000 of which were granted on March 8, 2015 and shall vest through March 8, 2018. Read SEC document |
| May 16, 2017 Filed May 17, 2017 23:36 UTC | DEXCOM INC DXCM · Entity 3114 | GiftCommon Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001093557-17-000123 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · EVP, Strategy & Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,424 F1 · shares: This transaction represents a gift of securities made by the reporting person. This is not a market transaction, thus no price has been reported. Transferor retains no beneficial or voting interest in the transferred shares. F2 · balance_after: Included in this number are 67,843 unvested restricted stock units, 27,510 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 25,333 of which were granted on March 8, 2016 and shall vest through March 8, 2019 and 15,000 of which were granted on March 8, 2015 and shall vest through March 8, 2018. Read SEC document |
| April 24, 2017 Filed Apr 26, 2017 23:04 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,450 | $75.89 | $110,040.94 |
DisclosureSEC source: 0001093557-17-000107 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · EVP, Strategy & Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,424 F1 · shares: On December 06, 2016 Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $75.60 to $76.11. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 67,843 unvested restricted stock units, 27,510 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 25,333 of which were granted on March 8, 2016 and shall vest through March 8, 2019 and 15,000 of which were granted on March 8, 2015 and shall vest through March 8, 2019. Read SEC document |
| March 23, 2017 Filed Mar 24, 2017 21:54 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 3,987 | $76.25 | $304,005.56 |
DisclosureSEC source: 0001093557-17-000095 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · EVP, Strategy & Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,874 F1 · shares: On December 06, 2016 Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $75.80 to $76.85. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 67,843 unvested restricted stock units, 27,510 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 25,333 of which were granted on March 8, 2016 and shall vest through March 8, 2019 and 15,000 of which were granted on March 8, 2015 and shall vest through March 8, 2019. Read SEC document |
| March 10, 2017 Filed Mar 11, 2017 01:49 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 6,694 | $77.55 | $519,123.72 |
DisclosureSEC source: 0001093557-17-000066 · edgardoc.xml · nonDerivative · entry 4 Pacelli Steven Robert · CIK 0001359098 · EVP, Strategy & Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,861 F3 · shares: These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted. F2 · balance_after: Included in this number are 67,843 unvested restricted stock units, 27,510 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 25,333 of which were granted on March 8, 2016 and shall vest through March 8, 2019 and 15,000 of which were granted on March 8, 2015 and shall vest through March 8, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.